Background parenchymal uptake on molecular breast imaging as a breast cancer risk factor: a case-control study
- PMID: 27113363
- PMCID: PMC4845425
- DOI: 10.1186/s13058-016-0704-6
Background parenchymal uptake on molecular breast imaging as a breast cancer risk factor: a case-control study
Abstract
Background: Molecular breast imaging (MBI) is a functional test used for supplemental screening of women with mammographically dense breasts. Additionally, MBI depicts variable levels of background parenchymal uptake (BPU) within nonmalignant, dense fibroglandular tissue. We investigated whether BPU is a risk factor for breast cancer.
Methods: We conducted a retrospective case-control study of 3027 eligible women who had undergone MBI between February 2004 and February 2014. Sixty-two incident breast cancer cases were identified. A total of 179 controls were matched on age, menopausal status, and MBI year. Two radiologists blinded to case status independently assessed BPU as one of four categories: photopenic, minimal to mild, moderate, or marked. Conditional logistic regression analysis was performed to estimate the associations (OR) of BPU categories (moderate or marked vs. minimal to mild or photopenic) and breast cancer risk, adjusted for other risk factors.
Results: The median age was 60.2 years (range 38-86 years) for cases vs. 60.2 years (range 38-88 years) for controls (p = 0.88). Women with moderate or marked BPU had a 3.4-fold (95 % CI 1.6-7.3) and 4.8-fold (95 % CI 2.1-10.8) increased risk of breast cancer, respectively, compared with women with photopenic or minimal to mild BPU, for two radiologists. The results were similar after adjustment for BI-RADS density (OR 3.3 [95 % CI 1.6-7.2] and OR 4.6 [95 % CI 2.1-10.5]) or postmenopausal hormone use (OR 3.6 [95 % CI 1.7-7.7] and OR 5.0 [95 % CI 2.2-11.4]). The association of BPU with breast cancer remained in analyses limited to postmenopausal women only (OR 3.8 [95 % CI 1.5-9.3] and OR 4.1 [95 % CI 1.6-10.2]) and invasive breast cancer cases only (OR 3.6 [95 % CI 1.5-8.8] and OR 4.4 [95 % CI 1.7-11.1]). Variable BPU was observed among women with similar mammographic density; the distribution of BPU categories differed across density categories (p < 0.0001).
Conclusions: This study provides the first evidence for BPU as a risk factor for breast cancer. Among women with dense breasts, who comprise >40 % of the screening population, BPU may serve as a functional imaging biomarker to identify the subset at greatest risk.
Keywords: Breast cancer risk; Breast density; Mammography; Molecular breast imaging; Tc-99m sestamibi.
Figures



Similar articles
-
Background Parenchymal Uptake on Molecular Breast Imaging and Breast Cancer Risk: A Cohort Study.AJR Am J Roentgenol. 2021 May;216(5):1193-1204. doi: 10.2214/AJR.20.23854. Epub 2021 Mar 3. AJR Am J Roentgenol. 2021. PMID: 32755210 Free PMC article.
-
Advances and Future Directions in Molecular Breast Imaging.J Nucl Med. 2022 Jan;63(1):17-21. doi: 10.2967/jnumed.121.261988. Epub 2021 Dec 9. J Nucl Med. 2022. PMID: 34887334 Free PMC article. Review.
-
Quantitative background parenchymal uptake on molecular breast imaging and breast cancer risk: a case-control study.Breast Cancer Res. 2018 Jun 5;20(1):46. doi: 10.1186/s13058-018-0973-3. Breast Cancer Res. 2018. PMID: 29871661 Free PMC article.
-
Background parenchymal uptake during molecular breast imaging and associated clinical factors.AJR Am J Roentgenol. 2015 Mar;204(3):W363-70. doi: 10.2214/AJR.14.12979. AJR Am J Roentgenol. 2015. PMID: 25714323 Free PMC article.
-
Current Concepts in Molecular Breast Imaging.J Breast Imaging. 2025 Jan 25;7(1):104-118. doi: 10.1093/jbi/wbae076. J Breast Imaging. 2025. PMID: 39692400 Review.
Cited by
-
Background Parenchymal Uptake on Molecular Breast Imaging and Breast Cancer Risk: A Cohort Study.AJR Am J Roentgenol. 2021 May;216(5):1193-1204. doi: 10.2214/AJR.20.23854. Epub 2021 Mar 3. AJR Am J Roentgenol. 2021. PMID: 32755210 Free PMC article.
-
Classification of Background Parenchymal Uptake on Molecular Breast Imaging Using a Convolutional Neural Network.JCO Clin Cancer Inform. 2019 Feb;3:1-11. doi: 10.1200/CCI.18.00133. JCO Clin Cancer Inform. 2019. PMID: 30807208 Free PMC article.
-
Advances and Future Directions in Molecular Breast Imaging.J Nucl Med. 2022 Jan;63(1):17-21. doi: 10.2967/jnumed.121.261988. Epub 2021 Dec 9. J Nucl Med. 2022. PMID: 34887334 Free PMC article. Review.
-
Impact of short-term low-dose tamoxifen on molecular breast imaging background parenchymal uptake: a pilot study.Breast Cancer Res. 2019 Mar 8;21(1):38. doi: 10.1186/s13058-019-1120-5. Breast Cancer Res. 2019. PMID: 30850011 Free PMC article. Clinical Trial.
-
Quantitative background parenchymal uptake on molecular breast imaging and breast cancer risk: a case-control study.Breast Cancer Res. 2018 Jun 5;20(1):46. doi: 10.1186/s13058-018-0973-3. Breast Cancer Res. 2018. PMID: 29871661 Free PMC article.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical